xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06016946</url>
    </required_header>
    <id_info>
      <org_study_id>1016</org_study_id>
      <nct_id>NCT06016946</nct_id>
    </id_info>
    <brief_title>Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study</brief_title>
    <acronym>UNIFAI</acronym>
    <official_title>Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Friedreich's Ataxia Research Alliance</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Friedreich's Ataxia Research Alliance</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This project is a global, multicenter, prospective, observational natural history study that&#xD;
        can be used to understand the disease progression and support the development of safe and&#xD;
        effective drugs and biological products for Friedreich ataxia.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The UNIFAI Natural History Study of Friedreich's Ataxia (FA) is a global research study&#xD;
        designed to provide a deep and evolving understanding of the natural history of this rare and&#xD;
        debilitating genetic disorder as well as inform clinical trial design and implementation.&#xD;
  &#xD;
        Friedreich's Ataxia is a rare, inherited, multi-system condition characterized by progressive&#xD;
        neurological and cardiac symptoms. It is caused by mutations in the FXN (frataxin) gene.&#xD;
  &#xD;
        The UNIFAI study is a prospective, longitudinal, observational study, which means that all&#xD;
        data will be captured at study visits conducted over time according to a single protocol for&#xD;
        all sites. This study will recruit participants with FA worldwide, to be assessed annually&#xD;
        for up to 25 years. Study participation involves yearly study visits with data collected from&#xD;
        medical records and history along with clinical outcome assessments including, neurological&#xD;
        exams, timed walking tests, upper limb function measures, and patient-reported quality of&#xD;
        life assessments, with the option for sites to collect additional ancillary measures related&#xD;
        to speech, vision, fatigue, balance and cognition.&#xD;
  &#xD;
        This global, multicenter study is a harmonization of two well-established, long-standing&#xD;
        natural history studies in FA that have provided a framework for further investigation of&#xD;
        clinical measures that can quantitatively assess FA: FACOMS (US, Canada, Australia, New&#xD;
        Zealand, and India) and EFACTS (European countries). These studies have been conducted in&#xD;
        parallel with many similarities in study conduct. Uniting these two existing studies and&#xD;
        groups of researchers gives greater power to data previously collected as well as future&#xD;
        data. It also continues efforts to expand the network of clinical research centers&#xD;
        specializing in FA called the FA-Global Clinical Consortium.&#xD;
  &#xD;
        Due to advances in understanding the genetic and cellular dysfunction of FA that lead to&#xD;
        symptoms observed in affected individuals, there has been significant growth in the discovery&#xD;
        and development of therapeutic approaches, many currently being evaluated in clinical trials&#xD;
        and a first approved treatment in the United States in 2023. The UNIFAI study aims to build&#xD;
        upon this momentum by focusing on several key objectives.&#xD;
  &#xD;
        UNIFAI will assess the natural history of FA by collecting data from diagnosed individuals of&#xD;
        all ages and stages of disease progression. The data collected includes demographics, medical&#xD;
        history, medications, neurological and functional assessments, cardiac examinations,&#xD;
        laboratory studies, and health questionnaires. The study will assess and evaluate clinical&#xD;
        outcomes in individuals with FA, such as disease progression, symptom severity, and overall&#xD;
        quality of life, by various factors that might influence such outcomes such as genetic&#xD;
        mutation, demographics (age, geography), co-existing conditions, medications, or treatments.&#xD;
        By tracking outcomes over time, researchers aim to discern patterns, trends, and potential&#xD;
        variations in subgroups or in the effectiveness of therapies or interventions across a&#xD;
        diverse group of participants.&#xD;
  &#xD;
        The UNIFAI study will play a pivotal role in identifying clinical milestones and changes in&#xD;
        natural history over time as new treatments emerge. The study will be able to monitor how&#xD;
        these interventions alter the trajectory of the disease, potentially leading to the&#xD;
        identification of crucial tipping points, disease landmarks, or stages where interventions&#xD;
        can be most impactful. This study has the potential to significantly improve our&#xD;
        understanding of FA and lead to more effective treatments and improved outcomes for those&#xD;
        living with FA.&#xD;
  &#xD;
        The study aims to inform clinical trial design and the development and validation of novel&#xD;
        clinical outcome assessments and biomarkers that can be used in clinical trials. The UNIFAI&#xD;
        study will capture data from a wide and diverse cohort of individuals with FA so that this&#xD;
        dataset can be used to inform the selection of inclusion and exclusion criteria and power&#xD;
        calculations for trial designs with specific clinical outcome measures.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">June 28, 2023</start_date>
    <completion_date type="Anticipated">January 28, 2048</completion_date>
    <primary_completion_date type="Anticipated">January 28, 2048</primary_completion_date>
    <study_type>Observational [Patient Registry]</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Case-Only</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <target_duration>25 Years</target_duration>
    <primary_outcome>
      <measure>Change in modified Friedreich Ataxia Rating Scale (mFARS) Score</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>The modified Friedreich Ataxia Rating Scale (mFARS) is a disease-specific scale that measures progression of neurological effects of FA. The mFARS is a validated and reliable scale; comprised of the neurologic component of the FARS and evaluates bulbar, upper limb, lower limb, and upright stability/gait function. For each item, responses categorize the corresponding neurological finding, and the findings are assigned a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The score ranges from 0 to 93. The score will be compared to the previous year annually for up to 25 years.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change in Scale for the Assessment and Rating of Ataxia (SARA) Score</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>The Scale for the Assessment and Rating of Ataxia (SARA) is a semi-quantitative assessment of ataxia, measuring ataxia of upper limb, lower limb, gait, balance and speech. It has eight items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movement, and heel-shin slide. The total score ranges from 0 (no ataxia) to 40 (severe ataxia). The score will be compared to the previous year annually for up to 25 years.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change in FA Activities of Daily Living (ADL) Score</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>The FARS-ADL is a subsection of the FARS questionnaire that assesses activities of daily living, including speech, personal hygiene, feeding, and mobility. Participants rank each category using a scale of 0 (normal) to 4 (severe disability/ inability to carry out activity independently), with lower scores indicative of &quot;normal&quot; function/activity. The score will be compared to the previous year annually for up to 25 years.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change in Upright Stability (US) Score</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>The Upright Stability (US) assessment is part of the neurological examination within the Modified Friedreich Ataxia Rating Scale (mFARS). This component comprises nine items: sitting position, stance with feet apart, stance with feet apart and eyes closed, stance with feet together, stance with feet together and eyes closed, tandem stance, stance with dominant foot, tandem walk, and gait. The score ranges from 0 to 9, with a higher score reflecting poorer upright stability (i.e., greater neurological severity). The score will be compared to the previous year annually for up to 25 years.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Change in 9-hole peg test mean time (seconds)</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>The 9 Hole Peg Test (9HPT) examines finger dexterity and involves placing and removing nine pegs in a pegboard in the quickest possible time. Two consecutive trials of the dominant hand, followed immediately by two consecutive trials of the non-dominant hand, are undertaken. The average time in seconds taken to complete the task, for each of the dominant and non-dominant hand, is calculated. The 9HPT has high intra- and inter-rater reliability and is the most commonly used measure of upper limb function in FA. The score will be compared to the previous year annually for up to 25 years.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in Timed walk (25-foot or 8-meter) mean time (seconds)</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>The timed 25-foot/8-meter walk examines upright stability, balance and mobility and involves walking a predetermined distance. Two consecutive trials are undertaken. The average time in seconds taken to complete the task, is calculated. The score will be compared to the previous year annually for up to 25 years.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in Speech analysis scores</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>A battery of speech evaluations will be administered and recorded on a laptop for analysis, using Redenlab software. This will include: reading of a phonetically-balanced passage, sustained vowel sound, listing days of the week, repeating syllables, and a monologue task. This will form a measure of dysarthria. Redenlab is a US-Australian speech-testing company, https://redenlab.com. The score will be compared to the previous year annually for up to 25 years.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in Ataxia Instrumented Measures (AIMs)clinical severity score</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>The Ataxia Instrumented Measures (AIMs) system consists of three components: 1) the data logger which is either a spoon, cup or pendant each containing sensors, Wi-Fi and processor; 2) algorithms that distinguishes between movements made by control and users with ataxia and grades the severity of ataxia when detected; and 3) ataxia scores presented in a manner that has utility for clinicians (the AIM &quot;score&quot;). This score is continuous and features an ataxia severity threshold which has been established through the process of machine learning and is based on the separation between individuals with ataxia and control participants. Any value below the severity threshold of a specific device is expected for controls/very mild ataxia, and any value beyond is expected for individuals with moderate/severe ataxia. The score will be compared to the previous year annually for up to 25 years.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in Lower Contrast Letter Acuity test score</measure>
      <time_frame>Baseline, Year 1-25</time_frame>
      <description>Contrast letter acuity for vision will be assessed using back-lit Low-Contrast Sloan Letter Charts (LCSLCs). Participants will sit at an eye distance of 2 metres from the chart. Binocular vision will be assessed using participants' normal corrective lenses where relevant. Participants are required to read each letter on the chart. Three charts will be presented, with three different visual contrast levels: 100% (equivalent to high-contrast visual acuity), 2.5%, and 1.25%. The maximum total score across the three charts (number of letters read correctly) is 240. Scores for each individual chart will also be recorded.</description>
    </secondary_outcome>
    <enrollment type="Anticipated">3000</enrollment>
    <condition>Friedreich Ataxia</condition>
    <biospec_retention>Samples With DNA</biospec_retention>
    <biospec_descr>
      <textblock>
        Whole blood may be collected as a one-time procedure.&#xD;
      </textblock>
    </biospec_descr>
    <eligibility>
      <study_pop>
        <textblock>
          The study will include current participants from the existing FA-COMS and EFACTS natural&#xD;
          history studies as well as enroll new individuals with Friedreich ataxia (FA) and healthy&#xD;
          controls.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Both males and females of any age&#xD;
  &#xD;
            2. Individuals with Friedreich ataxia (FA): Participants that meet genetically confirmed&#xD;
               diagnosis of Friedreich ataxia&#xD;
  &#xD;
            3. Written informed consent provided&#xD;
  &#xD;
                 1. Informed consent must be obtained for all participants&#xD;
  &#xD;
                 2. For underage participants, they and the parent/ legally authorized representative&#xD;
                    have to sign the informed consent form, child assent (if applicable)&#xD;
  &#xD;
                 3. Persons who are not legally competent require the informed consent of their&#xD;
                    legally authorized representative&#xD;
  &#xD;
               Exclusion Criteria:&#xD;
  &#xD;
            4. Unable or unwilling to provide informed consent&#xD;
  &#xD;
            5. Acute or ongoing medical or other conditions that would interfere with the conduct and&#xD;
               assessments of the study&#xD;
  &#xD;
            6. For any reason in the opinion of the investigator, participant would be unlikely or&#xD;
               unable to comply with study protocol requirements.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>N/A</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>David Lynch, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Children's Hospital of Philadelphia</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Jorg B Schulz, Prof</last_name>
      <role>Principal Investigator</role>
      <affiliation>University Hospital, Aachen</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Cait Monette</last_name>
      <phone>16513291892</phone>
      <email>cait.monette@cureFA.org</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Jennifer Farmer</last_name>
      <phone>14848796160</phone>
      <email>jen.farmer@cureFA.org</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>UCLA Ataxia Center</name>
        <address>
          <city>Los Angeles</city>
          <state>California</state>
          <zip>90095</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Westley Ulit</last_name>
        <phone>310-206-8153</phone>
        <email>WUlit@mednet.ucla.edu</email>
      </contact>
      <investigator>
        <last_name>Susan Perlman, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>University of Colorado</name>
        <address>
          <city>Denver</city>
          <state>Colorado</state>
          <zip>80045</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Erin Dougherty</last_name>
        <phone>719-297-7032</phone>
        <email>erin.2.dougherty@cuanschutz.edu</email>
      </contact>
      <investigator>
        <last_name>Trevor Hawkins, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>University of Florida - Neurology</name>
        <address>
          <city>Gainesville</city>
          <state>Florida</state>
          <zip>32610</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>MacKenzi Coker</last_name>
        <phone>352-294-8706</phone>
        <email>mcoker@peds.ufl.edu</email>
      </contact>
      <investigator>
        <last_name>SH Subramony, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>USF Ataxia Research Center</name>
        <address>
          <city>Tampa</city>
          <state>Florida</state>
          <zip>33612</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>FA Study</last_name>
        <phone>813-947-5633</phone>
      </contact>
      <investigator>
        <last_name>Theresa Zesiewicz, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Emory University Hospital - Neurology</name>
        <address>
          <city>Atlanta</city>
          <state>Georgia</state>
          <zip>30329</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>UNIFAI Study</last_name>
        <phone>404-727-1509</phone>
      </contact>
      <investigator>
        <last_name>George Wilmot, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>University of Iowa, Stead Family Children's Hospital</name>
        <address>
          <city>Iowa City</city>
          <state>Iowa</state>
          <zip>52242</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Corey McDaniel</last_name>
        <phone>319-335-7498</phone>
        <email>corey-mcdaniel@uiowa.edu</email>
      </contact>
      <investigator>
        <last_name>Katherine Mathews, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Ohio State University - Neurology</name>
        <address>
          <city>Columbus</city>
          <state>Ohio</state>
          <zip>43221</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Marco Tellez</last_name>
        <phone>614-688-7837</phone>
        <email>marco.tellez@osumc.edu</email>
      </contact>
      <investigator>
        <last_name>Chad Hoyle, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Children's Hospital of Philadelphia</name>
        <address>
          <city>Philadelphia</city>
          <state>Pennsylvania</state>
          <zip>19104</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>FA Program</last_name>
        <phone>267-426-7538</phone>
        <email>FAPROGRAM@chop.edu</email>
      </contact>
      <investigator>
        <last_name>David Lynch, MD PhD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>St. Jude Children's Research Hospital</name>
        <address>
          <city>Memphis</city>
          <state>Tennessee</state>
          <zip>38105</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Colin Quillivan</last_name>
        <phone>901-595-6266</phone>
        <email>Colin.Quillivan@STJUDE.ORG</email>
      </contact>
      <investigator>
        <last_name>Richard Finkel, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Murdoch Childrens Research Institute</name>
        <address>
          <city>Parkville</city>
          <state>Victoria</state>
          <zip>3052</zip>
          <country>Australia</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Geneieve Tai</last_name>
        <phone>61 8341 6374</phone>
        <email>geneieve.tai@mcri.edu.au</email>
      </contact>
      <contact_backup>
        <last_name>Louise Corben</last_name>
        <phone>61 3 8341 6228</phone>
        <email>louise.corben@vcgs.org.au</email>
      </contact_backup>
      <investigator>
        <last_name>Martin Delatycki, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>The Hospital for Sick Children</name>
        <address>
          <city>Toronto</city>
          <state>Ontario</state>
          <zip>M5G 1X8</zip>
          <country>Canada</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Bianca Perro</last_name>
        <phone>1-416-813-7654 ext 228623</phone>
        <email>bianca.perro@sickkids.ca</email>
      </contact>
      <investigator>
        <last_name>Grace Yoon, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>CHUM - Hopital Notre-Dame</name>
        <address>
          <city>Montréal</city>
          <state>Quebec</state>
          <zip>h2x0a9</zip>
          <country>Canada</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Célia Parinot, PhD</last_name>
        <phone>514 890-8000</phone>
        <phone_ext>30154</phone_ext>
        <email>celia.parinot.chum@ssss.gouv.qc.ca</email>
      </contact>
      <investigator>
        <last_name>Antoine Duquette, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>All India Institute of Medical Sciences (AIIMS)</name>
        <address>
          <city>New Delhi</city>
          <state>NCT</state>
          <zip>110020</zip>
          <country>India</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>AHMAD ISTAQ</last_name>
        <phone>+91-11-26546688</phone>
        <email>ishtox@gmail.com</email>
      </contact>
      <contact_backup>
        <last_name>SHWETA SAHANI</last_name>
        <phone>+91-11-26588500</phone>
        <email>sahni.shweta29@gmail.com</email>
      </contact_backup>
      <investigator>
        <last_name>Achal Srivastava, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
      <investigator>
        <last_name>Mohammed Faruq, M.B.B.S., PhD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Auckland City Hospital</name>
        <address>
          <city>Auckland</city>
          <zip>1023</zip>
          <country>New Zealand</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Juno Barnett Collins</last_name>
        <phone>+64 21 028 43954</phone>
        <email>juno.barnett.collins@auckland.ac.nz</email>
      </contact>
      <investigator>
        <last_name>Richard Roxburgh, BSC MB PhD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>Australia</country>
      <country>Canada</country>
      <country>India</country>
      <country>New Zealand</country>
      <country>United States</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 18, 2023</study_first_submitted>
    <study_first_submitted_qc>August 23, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 30, 2023</study_first_posted>
    <last_update_submitted>August 23, 2023</last_update_submitted>
    <last_update_submitted_qc>August 23, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 30, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Rare Disease</keyword>
    <keyword>Neuro-degenerative disease</keyword>
    <keyword>Ataxia</keyword>
    <keyword>Neurodegenerative Diseases</keyword>
    <keyword>Neurologic Manifestations</keyword>
    <keyword>Genetic Diseases, Inborn</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Ataxia</mesh_term>
      <mesh_term>Cerebellar Ataxia</mesh_term>
      <mesh_term>Friedreich Ataxia</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Undecided</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06016946
  org study id: 1016
  nct id: NCT06016946
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  This project is a global, multicenter, prospective, observational natural history study that
        can be used to understand the disease progression and support the development of safe and
        effective drugs and biological products for Friedreich ataxia.
  The UNIFAI Natural History Study of Friedreich's Ataxia (FA) is a global research study
        designed to provide a deep and evolving understanding of the natural history of this rare and
        debilitating genetic disorder as well as inform clinical trial design and implementation.
  
        Friedreich's Ataxia is a rare, inherited, multi-system condition characterized by progressive
        neurological and cardiac symptoms. It is caused by mutations in the FXN (frataxin) gene.
  
        The UNIFAI study is a prospective, longitudinal, observational study, which means that all
        data will be captured at study visits conducted over time according to a single protocol for
        all sites. This study will recruit participants with FA worldwide, to be assessed annually
        for up to 25 years. Study participation involves yearly study visits with data collected from
        medical records and history along with clinical outcome assessments including, neurological
        exams, timed walking tests, upper limb function measures, and patient-reported quality of
        life assessments, with the option for sites to collect additional ancillary measures related
        to speech, vision, fatigue, balance and cognition.
  
        This global, multicenter study is a harmonization of two well-established, long-standing
        natural history studies in FA that have provided a framework for further investigation of
        clinical measures that can quantitatively assess FA: FACOMS (US, Canada, Australia, New
        Zealand, and India) and EFACTS (European countries). These studies have been conducted in
        parallel with many similarities in study conduct. Uniting these two existing studies and
        groups of researchers gives greater power to data previously collected as well as future
        data. It also continues efforts to expand the network of clinical research centers
        specializing in FA called the FA-Global Clinical Consortium.
  
        Due to advances in understanding the genetic and cellular dysfunction of FA that lead to
        symptoms observed in affected individuals, there has been significant growth in the discovery
        and development of therapeutic approaches, many currently being evaluated in clinical trials
        and a first approved treatment in the United States in 2023. The UNIFAI study aims to build
        upon this momentum by focusing on several key objectives.
  
        UNIFAI will assess the natural history of FA by collecting data from diagnosed individuals of
        all ages and stages of disease progression. The data collected includes demographics, medical
        history, medications, neurological and functional assessments, cardiac examinations,
        laboratory studies, and health questionnaires. The study will assess and evaluate clinical
        outcomes in individuals with FA, such as disease progression, symptom severity, and overall
        quality of life, by various factors that might influence such outcomes such as genetic
        mutation, demographics (age, geography), co-existing conditions, medications, or treatments.
        By tracking outcomes over time, researchers aim to discern patterns, trends, and potential
        variations in subgroups or in the effectiveness of therapies or interventions across a
        diverse group of participants.
  
        The UNIFAI study will play a pivotal role in identifying clinical milestones and changes in
        natural history over time as new treatments emerge. The study will be able to monitor how
        these interventions alter the trajectory of the disease, potentially leading to the
        identification of crucial tipping points, disease landmarks, or stages where interventions
        can be most impactful. This study has the potential to significantly improve our
        understanding of FA and lead to more effective treatments and improved outcomes for those
        living with FA.
  
        The study aims to inform clinical trial design and the development and validation of novel
        clinical outcome assessments and biomarkers that can be used in clinical trials. The UNIFAI
        study will capture data from a wide and diverse cohort of individuals with FA so that this
        dataset can be used to inform the selection of inclusion and exclusion criteria and power
        calculations for trial designs with specific clinical outcome measures.
  observational model: Case-Only
  time perspective: Prospective
  measure: Change in modified Friedreich Ataxia Rating Scale (mFARS) Score
  time frame: Baseline, Year 1-25
  description: The modified Friedreich Ataxia Rating Scale (mFARS) is a disease-specific scale that measures progression of neurological effects of FA. The mFARS is a validated and reliable scale; comprised of the neurologic component of the FARS and evaluates bulbar, upper limb, lower limb, and upright stability/gait function. For each item, responses categorize the corresponding neurological finding, and the findings are assigned a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The score ranges from 0 to 93. The score will be compared to the previous year annually for up to 25 years.
  measure: Change in Scale for the Assessment and Rating of Ataxia (SARA) Score
  time frame: Baseline, Year 1-25
  description: The Scale for the Assessment and Rating of Ataxia (SARA) is a semi-quantitative assessment of ataxia, measuring ataxia of upper limb, lower limb, gait, balance and speech. It has eight items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movement, and heel-shin slide. The total score ranges from 0 (no ataxia) to 40 (severe ataxia). The score will be compared to the previous year annually for up to 25 years.
  measure: Change in FA Activities of Daily Living (ADL) Score
  time frame: Baseline, Year 1-25
  description: The FARS-ADL is a subsection of the FARS questionnaire that assesses activities of daily living, including speech, personal hygiene, feeding, and mobility. Participants rank each category using a scale of 0 (normal) to 4 (severe disability/ inability to carry out activity independently), with lower scores indicative of "normal" function/activity. The score will be compared to the previous year annually for up to 25 years.
  measure: Change in Upright Stability (US) Score
  time frame: Baseline, Year 1-25
  description: The Upright Stability (US) assessment is part of the neurological examination within the Modified Friedreich Ataxia Rating Scale (mFARS). This component comprises nine items: sitting position, stance with feet apart, stance with feet apart and eyes closed, stance with feet together, stance with feet together and eyes closed, tandem stance, stance with dominant foot, tandem walk, and gait. The score ranges from 0 to 9, with a higher score reflecting poorer upright stability (i.e., greater neurological severity). The score will be compared to the previous year annually for up to 25 years.
  measure: Change in 9-hole peg test mean time (seconds)
  time frame: Baseline, Year 1-25
  description: The 9 Hole Peg Test (9HPT) examines finger dexterity and involves placing and removing nine pegs in a pegboard in the quickest possible time. Two consecutive trials of the dominant hand, followed immediately by two consecutive trials of the non-dominant hand, are undertaken. The average time in seconds taken to complete the task, for each of the dominant and non-dominant hand, is calculated. The 9HPT has high intra- and inter-rater reliability and is the most commonly used measure of upper limb function in FA. The score will be compared to the previous year annually for up to 25 years.
  measure: Change in Timed walk (25-foot or 8-meter) mean time (seconds)
  time frame: Baseline, Year 1-25
  description: The timed 25-foot/8-meter walk examines upright stability, balance and mobility and involves walking a predetermined distance. Two consecutive trials are undertaken. The average time in seconds taken to complete the task, is calculated. The score will be compared to the previous year annually for up to 25 years.
  measure: Change in Speech analysis scores
  time frame: Baseline, Year 1-25
  description: A battery of speech evaluations will be administered and recorded on a laptop for analysis, using Redenlab software. This will include: reading of a phonetically-balanced passage, sustained vowel sound, listing days of the week, repeating syllables, and a monologue task. This will form a measure of dysarthria. Redenlab is a US-Australian speech-testing company, https://redenlab.com. The score will be compared to the previous year annually for up to 25 years.
  measure: Change in Ataxia Instrumented Measures (AIMs)clinical severity score
  time frame: Baseline, Year 1-25
  description: The Ataxia Instrumented Measures (AIMs) system consists of three components: 1) the data logger which is either a spoon, cup or pendant each containing sensors, Wi-Fi and processor; 2) algorithms that distinguishes between movements made by control and users with ataxia and grades the severity of ataxia when detected; and 3) ataxia scores presented in a manner that has utility for clinicians (the AIM "score"). This score is continuous and features an ataxia severity threshold which has been established through the process of machine learning and is based on the separation between individuals with ataxia and control participants. Any value below the severity threshold of a specific device is expected for controls/very mild ataxia, and any value beyond is expected for individuals with moderate/severe ataxia. The score will be compared to the previous year annually for up to 25 years.
  measure: Change in Lower Contrast Letter Acuity test score
  time frame: Baseline, Year 1-25
  description: Contrast letter acuity for vision will be assessed using back-lit Low-Contrast Sloan Letter Charts (LCSLCs). Participants will sit at an eye distance of 2 metres from the chart. Binocular vision will be assessed using participants' normal corrective lenses where relevant. Participants are required to read each letter on the chart. Three charts will be presented, with three different visual contrast levels: 100% (equivalent to high-contrast visual acuity), 2.5%, and 1.25%. The maximum total score across the three charts (number of letters read correctly) is 240. Scores for each individual chart will also be recorded.
  Whole blood may be collected as a one-time procedure.
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: N/A
  maximum age: N/A
  healthy volunteers: Accepts Healthy Volunteers
  last name: David Lynch, MD
  role: Principal Investigator
  affiliation: Children's Hospital of Philadelphia
  last name: Jorg B Schulz, Prof
  role: Principal Investigator
  affiliation: University Hospital, Aachen
  last name: Cait Monette
  phone: 16513291892
  email: cait.monette@cureFA.org
  last name: Jennifer Farmer
  phone: 14848796160
  email: jen.farmer@cureFA.org
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  contact backup: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  contact backup: 
  investigator: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  country: Australia
  country: Canada
  country: India
  country: New Zealand
  country: United States
  responsible party type: Sponsor
  mesh term: Ataxia
  mesh term: Cerebellar Ataxia
  mesh term: Friedreich Ataxia
  sharing ipd: Undecided